Regulations in 2021 required the addition of a volatility reduction agent (VRA) to dicamba spray mixtures for postemergence weed control. Understanding the impact of VRAs on weed control, droplet dynamics, and spray pH is essential.

RESULTS:

Adding glyphosate to dicamba decreased the solution pH by 0.63 to 1.85 units. Across locations, potassium carbonate increased the tank‐mixture pH by 0.85 to 1.65 units while potassium acetate raised the pH by 0.46 to 0.53 units. Glyphosate and dicamba in tank‐mixture reduced Palmer amaranth control by 14 percentage points compared to dicamba alone and decreased barnyardgrass control by 12 percentage points compared to glyphosate alone 4 weeks after application (WAA). VRAs resulted in a 5‐percentage point reduction in barnyardgrass control 4 WAA. Common ragweed, common lambsquarters, and giant ragweed control were unaffected by herbicide solution 4 WAA. Dicamba alone produced a larger average droplet size and had the fewest driftable fines (% volume < 200 μm). Potassium acetate produced a larger droplet size than potassium carbonate for Dv0.1and Dv0.5. The addition of glyphosate to dicamba decreased droplet size from the entire spray droplet spectrum (Dv0.1, Dv0.5, Dv0.9).

CONCLUSION:

A reduction in spray pH, droplet size, and weed control was observed from mixing dicamba and glyphosate. It may be advisable to avoid tank‐mixtures of these herbicides and instead, apply them sequentially to maximize effectiveness. VRAs differed in their impacts on spray solution pH and droplet dynamics, but resulted in a minimal negative to no impact on weed control. © 2022 The Authors.Pest Management Sciencepublished by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.

01 Dec 2021·Life sciencesQ3 · MEDICINE

N-acetyl l-aspartate and Triacetin modulate tumor suppressor MicroRNA and class I and II HDAC gene expression induce apoptosis in Glioblastoma cancer cells in vitro

Q3 · MEDICINE

Article

Author: Ramalingam, PrasannaSrinivasan ; Moparthi, Nageswara Rao ; Kurappalli, Rohil Kumar ; Mekala, Janaki Ramaiah

Glioblastoma multiforme (GBM), grade IV glioma and is aggressive, malignant primary brain cancer. Altered expression and activity of epigenetic proteins such as histone deacetylases (HDACs) are involved in GBM metastasis. Also, acetates are important to brain metabolites that regulate cell proliferation and apoptosis. Here, we have examined the effect of the acetates on the cell-cycle. U87MG cancer cells treated with N-acetyl l-aspartate (NAA) and sodium acetate have exhibited G1 phase cell-cycle arrest whereas U87MG cells treated with Triacetin (TA), and potassium acetate has induced G2/M cell cycle arrest. We have observed inhibition of histone deacetylase (HDAC) mRNA levels in acetate treated U87MG cells. Interestingly, acetates-treated U87MG cells have shown a significant reduction in the mRNA level of class II HDACs than class I HDACs. Acetate treated cells have exhibited an enhanced expression of various microRNAs such as miR-15b, miR-92, miR-101, miR-155, miR-199, miR-200, miR-223, miR-16, and miR-17 that are involved in the inhibition of cancer cell proliferation, invasion, migration, and angiogenesis. Further, these acetate molecules regulate genes involved in mammalian target of rapamycin complex 2 (mTORC2) such as mammalian stress-activated protein kinase-interacting protein (mSIN1), protein observed with Rictor 2 (Protor 2), and protein kinase C α (PKCα). The present study reveals the possible involvement of the mTORC2 complex during acetate-mediated HDAC inhibition, as well as microRNA modulation. Furthermore, molecular modeling studies were employed to understand the binding mode of these acetate molecules to mTOR, Rapamycin-insensitive companion of mammalian target of rapamycin (Rictor), and HDAC-8 proteins. Thus in this study, we have identified the pivotal role of acetates in the modulation of mTOR complex, epigenetic genes and provide structural as well as functional insights that will help in future drug discovery against GBM cancer therapy.

01 Dec 2018·Hospital pharmacy

Avoiding Patient Harm With Parenteral Nutrition During Electrolyte Shortages

Article

Author: McClellan, Nicole H. ; Minard, Gayle ; Brown, Eric W. ; Dickerson, Roland N. ; Maish, George O.

Purpose: We report a case of a patient with gastrointestinal dysmotility and substantial drainage losses who required parenteral nutrition (PN) and developed a non–anion gap metabolic acidosis secondary to a shortage of concurrent potassium acetate and sodium acetate PN additives. We describe how severe PN-associated metabolic consequences were averted during this acetate shortage. Summary: The patient with inability to swallow and significant weight loss was admitted to the hospital and given PN after failure to tolerate either gastric or jejunal feeding due to dysmotility and severe abdominal distension and discomfort. PN was initiated and the nasogastric and jejunal tubes were left to low intermittent suction or gravity drainage (average losses of 800 mL and 1600 mL daily, respectively) to reduce abdominal distension. The patient had been stable on PN for approximately 2 months prior to when a shortage in potassium acetate and sodium acetate occurred. As a result, potassium and sodium requirements had to be met with chloride and phosphate salts. The patient developed a non–anion gap metabolic acidosis after 11 days of acetate-free PN. Progression to severe acidemia was avoided by administration of sodium bicarbonate daily for 3 days and replacement of 0.9% sodium chloride supplemental intravenous fluid with lactated ringers solution. Conclusion: This case report illustrates that PN component shortages require clinicians to closely monitor patients who require PN. In addition, clinicians may need to use creative therapeutic strategies to avoid potential serious patient harm during PN component shortages.

News (Medical) associated with Potassium Acetate

04 Aug 2023

·firstwordpharma.com

Pfizer curbs distribution of some drugs from tornado-hit plant

In a recent letter to hospitals, Pfizer stated that it is limiting the distribution of some drugs manufactured at its plant in Rocky Mount, North Carolina, after the facility was damaged by a tornado last month. The inventory management update listed 12 injectable products that Pfizer will only distribute through emergency orders "due to their high medical need," noting that its action is effective "immediately and until further notice."Some versions of the listed drugs were already in short supply in the US prior to the tornado, according to a database from the American Society of Health-System Pharmacists. These include sodium chloride injections used to treat hyponatraemia, as well as a potassium acetate injection used for hypokalaemia.Also on the list are certain versions of dobutamine and dopamine, used to treat hypotension, low cardiac output and reduced perfusion of body organs due to shock, trauma and sepsis. According to Pfizer's letter, hospitals will be asked to provide their requested order quantity and average monthly demand or usage.Pfizer previously stated that the Rocky Mount facility accounted for 8% of all sterile injectable medicines used in US hospitals, spanning anaesthesia, analgesia, therapeutics, anti-infectives, and neuromuscular blockers. In a statement following the tornado, the company said the warehouse facility, which stores raw materials, packaging supplies and finished medicines, appeared to have suffered the most damage, while an initial assessment suggested there did not appear to be "any major damage" to the medicine production areas, although it has warned that there could be supply disruptions.It also said it was exploring alternative manufacturing locations for production across its other sites in the US and abroad, as well as through its network of partners. During the company's recent earnings call, CEO Albert Bourla said the drugmaker is still assessing how long it will take to bring the facility back online.Meanwhile, all other products manufactured at the Rocky Mount facility that are not mentioned on the list remain available in the distribution chain. "We believe this is the most responsible approach to enable equitable distribution of their remaining inventory as well as support continuity of patient care while we work to restart production," Meera Bhavsar, Pfizer's sterile injectables portfolio lead, wrote in the letter.

100 Deals associated with Potassium Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D01154	Potassium Acetate	B05XA17	DB14498

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypokalemia	US	Hospira, Inc.	20 Jul 1984

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis